Anita Gulati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anita Gulati has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Anil Kumar Mavi
Department of Pulmonary Medicine, Vallabhbhai Patel Chest Institute, University of Delhi
1 shared publication - Dhitri Borah
Biswanath College, Assam, India
1 shared publication Dushyant Kumar
1 shared publication- Indira Sarma
Department of Zoology, Biswanath College, Biswanath Chariali, Assam, 784176, India
1 shared publication Monisha Khanna
1 shared publication- Munendra Kumar
Department of Zoology, Rajiv Gandhi University
1 shared publication
Latest Publications
- 1 March 2026
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 27 (5) , 527-541
CAR-T Cell Therapy: Pioneering Immunotherapy Paradigms in Cancer Treatment
Cancer is a leading cause of death around the world. Cancer is still a complex disease over the years that needs to be cured. Traditional cytotoxic approaches, which have been used for years to treat neoplastic diseases, are limited due to the intricacy and low efficiency of cancer cells. Researchers are consequently pushed to seek more potent therapeutic strategies. Chimeric antigen receptor (CAR-T) cell therapy is one such innovative approach in which T lymphocytes are genetically engineered to target cancer cells. Despite the outstanding accomplishment in patients with haematological malignancies, CAR-T cell treatment has demonstrated minimal impact on solid tumors due to a number of obstacles, including proliferation, stability, trafficking, and fate within tumors. Furthermore, interactions between the host and tumour microenvironment with CAR-T cells significantly alter CAR-T cell activities. Designing and implementing these treatments additionally also requires a complex workforce. Overcoming these significant challenges, there is a requirement for innovative strategies for developing CAR-T cells with greater anti-tumor efficacy and reduced toxicity. In this review article, the current advancement in CAR-T cell technology in order to increase clinical efficacy in both solid and hematological tumors, as well as potential solutions to overcome the limitations of CAR-T cell therapy in both solid and haematological tumors.
- 1 March 2026
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 27 (5) , 527-541
CAR-T Cell Therapy: Pioneering Immunotherapy Paradigms in Cancer Treatment
Cancer is a leading cause of death around the world. Cancer is still a complex disease over the years that needs to be cured. Traditional cytotoxic approaches, which have been used for years to treat neoplastic diseases, are limited due to the intricacy and low efficiency of cancer cells. Researchers are consequently pushed to seek more potent therapeutic strategies. Chimeric antigen receptor (CAR-T) cell therapy is one such innovative approach in which T lymphocytes are genetically engineered to target cancer cells. Despite the outstanding accomplishment in patients with haematological malignancies, CAR-T cell treatment has demonstrated minimal impact on solid tumors due to a number of obstacles, including proliferation, stability, trafficking, and fate within tumors. Furthermore, interactions between the host and tumour microenvironment with CAR-T cells significantly alter CAR-T cell activities. Designing and implementing these treatments additionally also requires a complex workforce. Overcoming these significant challenges, there is a requirement for innovative strategies for developing CAR-T cells with greater anti-tumor efficacy and reduced toxicity. In this review article, the current advancement in CAR-T cell technology in order to increase clinical efficacy in both solid and hematological tumors, as well as potential solutions to overcome the limitations of CAR-T cell therapy in both solid and haematological tumors.
- Open Access
EasyABM: a lightweight and easy to use heterogeneous agent-based modelling tool written in Julia
Agent based modelling is a computational approach that aims to understand the behaviour of complex systems through simplified interactions of programmable objects in computer memory called agents. Agent based models (ABMs) are predominantly used in fields of biology, ecology, social sciences and economics where the systems of interest often consist of several interacting entities. In this work, we present a Julia package EasyABM.jl for simplifying the process of studying agent based models. EasyABM.jl provides an intuitive and easy to understand functional approach for building and analysing agent based models.
Open AccessEasyABM: a lightweight and easy to use heterogeneous agent-based modelling tool written in Julia
Agent based modelling is a computational approach that aims to understand the behaviour of complex systems through simplified interactions of programmable objects in computer memory called agents. Agent based models (ABMs) are predominantly used in fields of biology, ecology, social sciences and economics where the systems of interest often consist of several interacting entities. In this work, we present a Julia package EasyABM.jl for simplifying the process of studying agent based models. EasyABM.jl provides an intuitive and easy to understand functional approach for building and analysing agent based models.